Welcome to INSUPPORT
Dedicated to patient access

INSUPPORT was created by Indivior to help streamline the access and reimbursement processes on behalf of patients.

Please see the full Prescribing Information including BOXED WARNING and Medication Guide for SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use (CIII).

Please see the full Prescribing Information, Important Safety Information, and Medication Guide for SUBOXONE® (buprenorphine/naloxone sublingual film).

IMPORTANT INFORMATION FOR SUBLOCADE

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY

  • Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.

  • Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.